Following the launch of France’s ERPPAD Phase 3 trial, Julien Chupin and Amandine Luquiens have contributed a guest article explaining the research behind the study. ERPPAD investigates whether psilocybin, added to usual care, can help prevent relapse in people with alcohol use disorder and persistent depressive symptoms after detoxification. It builds on the team’s earlier Psilocybin Alcohol Depression (PAD) pilot study.